Company Overview and News

8
Walmart Bests Whole Foods in Study of Food Supply's Human Toll - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TESO WFM KR TSCDY TSCDF 42R TSCO

10
The Singapore stocks to watch during the Trump-Kim summit

2018-06-10 scmp
There’s more than one way to play the Trump-Kim summit in the world of stocks. Apart from the obvious North Asian and US equities, there’s another geography investors can consider: Singapore – and its consumer stocks, to be precise.
S07 C6L SK7 CDGLF BTKGF 5DA ACTRF SHALF SINGY Q5T O39 GIGNY 42R A68U G13 0069 CDGLY H15 A34 GIGNF FHOSY J85 SHALY SINGF

0
Hong Kong's Tsui Wah to open first Singapore outlet in Clarke Quay on Jun 15

2018-05-30 channelnewsasia
SINGAPORE: Hong Kong's famous Tsui Wah eatery will open its first Singapore outlet at Clarke Quay on Jun 15, the chain announced on Wednesday (May 30).
42R

0
Tsui Wah Singapore to open Clarke Quay outlet on Jun 15

2018-05-30 channelnewsasia
SINGAPORE: Hong Kong's famous Tsui Wah eatery will open its first Singapore outlet at Clarke Quay on Jun 15, the chain announced on Wednesday (May 30).
42R

0
Gaming industry still a safe bet in PH amid changing rules, rising competition

2018-05-28 business.inquirer.net
In a country which is 80 percent Catholic, it would seem surprising that the gaming industry has taken off: the Philippines has become one of the key markets for casinos in Asia after Macau and Singapore.
0027 BBRRF BLOOM GXYEF GXYYY 42R

0
Hong Kong's Tsui Wah to open first Singapore outlet at Clarke Quay - Channel NewsAsia

2018-03-15 channelnewsasia
SINGAPORE: Hong Kong's famous Tsui Wah eatery will open its first Singapore outlet at Clarke Quay, the chain told Channel NewsAsia on Thursday (Mar 15).
42R

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...